Figure 6: Broad spectrum, antifungal activity of GW.
A, Checkerboard analysis of antifungal activity for combination of GW with the conventional antifungal fluconazole (FLC) against wild-type and azole-tolerant C. albicans. Fungus was exposed to the indicated 2-fold serial dilutions of each compound in YPD medium for 48-hours. Relative growth inhibition was monitored by OD600 and displayed in heat-map format as described in Figure 1. Each colored box represents the mean of duplicate determinations. Color scale for relative growth inhibition is provided at the bottom of the figure and applies to all panels. Testing was repeated as an independent biological replicate to confirm results. Fractional Inhibitory Concentration 80 (FIC80) index values are indicated on checkerboards where applicable. FIC80 <0.5 indicates synergy. B, Checkerboard analysis of antifungal activity for combination of GW and FLC (left) or GW and caspofungin (CF, right) against a drug-resistant clinical isolate of C. auris. Experimental design and display of results are the same as (a). The testing was repeated as an independent biological replicate to confirm results. C, Checkerboard analysis of antifungal activity for combination of GW with the clinically relevant antifungal fluconazole (FLC) against Cryptococcus neoformans. Experimental design and display of results are the same as (A). The testing was repeated as an independent biological replicate to confirm results. Fractional Inhibitory Concentration 80 (FIC80) analysis was not performed in context of single agent activity at lowest concentration of GW tested. (See also Figure S5 and S6).